Phase 1/2 study to investigate safety and efficacy of IMM-101 in locally advanced pancreatic cancer

Uxbridge, UK, 13 September 2019 – Immodulon, the immuno-oncology company, today announces that the Department of Surgery at the Erasmus Medical Center in Rotterdam is conducting an investigator-initiated open label, non-randomised phase I/II study in locally advanced pancreatic cancer (LAPC). The LAPC-2 study will investigate the safety of combining our lead candidate, IMM-101 (heat-killed Mycobacterium obuense), when administered after combination chemotherapy (FOLFIRINOX) and with stereotactic body radiation therapy (SBRT) prior to possible surgery.

Approximately 30-40% of patients with pancreatic cancer present with LAPC. The current standard of care of FOLFIRINOX and SBRT results in one third of this patient group being able to undergo surgery. Adding IMM-101 to this current standard of care may optimise the immunogenic anti-tumour effect of radiation therapy, through its activation and maturation of antigen presenting cells.

Initially, 20 patients will be recruited to ensure the safety of inclusion of IMM-101 in this regimen prior to surgery, with subsequent enrolment of up to 38 patients, provided the combination does not impose an unacceptable, additional safety burden to these patients.

For more information about this study, please click here.